1277 related articles for article (PubMed ID: 33767706)
1. The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic.
Shah P; Canziani GA; Carter EP; Chaiken I
Front Immunol; 2021; 12():637651. PubMed ID: 33767706
[TBL] [Abstract][Full Text] [Related]
2. Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.
Srivastava V; Niu L; Phadke KS; Bellaire BH; Cho MW
Front Immunol; 2021; 12():637982. PubMed ID: 33777030
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
6. Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells.
Wietschel KA; Fechtner K; Antileo E; Abdurrahman G; Drechsler CA; Makuvise MK; Rose R; Voß M; Krumbholz A; Michalik S; Weiss S; Ulm L; Franikowski P; Fickenscher H; Bröker BM; Raafat D; Holtfreter S
Front Immunol; 2024; 15():1382911. PubMed ID: 38807606
[TBL] [Abstract][Full Text] [Related]
7. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
8. Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs.
Thura M; Sng JXE; Ang KH; Li J; Gupta A; Hong JM; Hong CW; Zeng Q
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34519332
[TBL] [Abstract][Full Text] [Related]
9. Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike.
Crowley AR; Natarajan H; Hederman AP; Bobak CA; Weiner JA; Wieland-Alter W; Lee J; Bloch EM; Tobian AAR; Redd AD; Blankson JN; Wolf D; Goetghebuer T; Marchant A; Connor RI; Wright PF; Ackerman ME
Elife; 2022 Mar; 11():. PubMed ID: 35289271
[TBL] [Abstract][Full Text] [Related]
10. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.
Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z;
Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794
[TBL] [Abstract][Full Text] [Related]
11. A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.
Kim E; Weisel FJ; Balmert SC; Khan MS; Huang S; Erdos G; Kenniston TW; Carey CD; Joachim SM; Conter LJ; Weisel NM; Okba NMA; Haagmans BL; Percivalle E; Cassaniti I; Baldanti F; Korkmaz E; Shlomchik MJ; Falo LD; Gambotto A
Eur J Immunol; 2021 Jul; 51(7):1774-1784. PubMed ID: 33772778
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
Wang Y; Wang L; Cao H; Liu C
J Med Virol; 2021 Feb; 93(2):892-898. PubMed ID: 32691875
[TBL] [Abstract][Full Text] [Related]
13. A vaccine built from potential immunogenic pieces derived from the SARS-CoV-2 spike glycoprotein: A computational approximation.
Marchan J
J Immunol Methods; 2022 Mar; 502():113216. PubMed ID: 35007561
[TBL] [Abstract][Full Text] [Related]
14. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals.
Zhu Y; Yu D; Han Y; Yan H; Chong H; Ren L; Wang J; Li T; He Y
Sci Adv; 2020 Nov; 6(45):. PubMed ID: 33036961
[TBL] [Abstract][Full Text] [Related]
15. Identification of HLA-A*24:02-Restricted CTL Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 and Analysis of Their Conservation Using the Mutation Database of SARS-CoV-2 Variants.
Takagi A; Matsui M
Microbiol Spectr; 2021 Dec; 9(3):e0165921. PubMed ID: 34937174
[TBL] [Abstract][Full Text] [Related]
16. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
17. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
Moyo-Gwete T; Madzivhandila M; Makhado Z; Ayres F; Mhlanga D; Oosthuysen B; Lambson BE; Kgagudi P; Tegally H; Iranzadeh A; Doolabh D; Tyers L; Chinhoyi LR; Mennen M; Skelem S; Marais G; Wibmer CK; Bhiman JN; Ueckermann V; Rossouw T; Boswell M; de Oliveira T; Williamson C; Burgers WA; Ntusi N; Morris L; Moore PL
N Engl J Med; 2021 Jun; 384(22):2161-2163. PubMed ID: 33826816
[No Abstract] [Full Text] [Related]
18. A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques.
Li Y; Bi Y; Xiao H; Yao Y; Liu X; Hu Z; Duan J; Yang Y; Li Z; Li Y; Zhang H; Ding C; Yang J; Li H; He Z; Liu L; Hu G; Liu S; Che Y; Wang S; Li Q; Lu S; Cun W
Emerg Microbes Infect; 2021 Dec; 10(1):342-355. PubMed ID: 33555988
[TBL] [Abstract][Full Text] [Related]
19. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
20. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
